Ekso Bionics (NASDAQ:EKSO) Share Price Crosses Above Fifty Day Moving Average – What’s Next?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)’s stock price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $6.87 and traded as high as $9.70. Ekso Bionics shares last traded at $9.52, with a volume of 310,124 shares.

Wall Street Analyst Weigh In

EKSO has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ekso Bionics in a research report on Monday, December 22nd. HC Wainwright lowered Ekso Bionics from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 31st. Finally, Wall Street Zen raised Ekso Bionics to a “hold” rating in a research note on Saturday, December 13th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $10.50.

Ekso Bionics Stock Up 5.0%

The firm has a market cap of $24.94 million, a PE ratio of -1.68 and a beta of 0.80. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.66 and a quick ratio of 1.09. The business has a fifty day moving average price of $6.87 and a two-hundred day moving average price of $5.21.

Insider Activity at Ekso Bionics

In other Ekso Bionics news, CFO Jerome Wong sold 11,288 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $4.80, for a total value of $54,182.40. Following the completion of the sale, the chief financial officer owned 26,009 shares in the company, valued at $124,843.20. This represents a 30.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Scott G. Davis sold 23,315 shares of Ekso Bionics stock in a transaction on Monday, November 10th. The shares were sold at an average price of $4.80, for a total transaction of $111,912.00. Following the sale, the chief executive officer directly owned 78,777 shares of the company’s stock, valued at $378,129.60. This trade represents a 22.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 6.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Consolidated Portfolio Review Corp acquired a new stake in Ekso Bionics in the third quarter valued at approximately $333,000. Citadel Advisors LLC acquired a new stake in shares of Ekso Bionics in the 3rd quarter valued at $198,000. Shay Capital LLC acquired a new stake in shares of Ekso Bionics in the 3rd quarter valued at $67,000. Finally, Virtu Financial LLC bought a new stake in Ekso Bionics in the third quarter worth $57,000. 6.42% of the stock is owned by institutional investors and hedge funds.

About Ekso Bionics

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.